Details

Effective targeting of E2F1 transcription factor via siRNA gene electrotransfer in HT-29 colorectal carcinoma xenografts
ID Jesenko, Tanja (Author), ID Kranjc Brezar, Simona (Author), ID Pišljar, Živa (Author), ID Božič, Tim (Author), ID Markelc, Boštjan (Author), ID Cazzato, Monica (Author), ID Grassi, Gabriele (Author), ID Čemažar, Maja (Author)

.pdfPDF - Presentation file, Download (4,40 MB)
MD5: D3BF949517000A3A0EE3C24A8DD1A7E8
URLURL - Source URL, Visit https://www.sciencedirect.com/science/article/pii/S1567539425000970 This link opens in a new window

Abstract
Colorectal cancer (CRC) remains a significant global health concern, with survival outcomes heavily dependent on the stage at diagnosis. Targeted therapies offer a promising approach to improve patient outcomes, particularly by addressing molecular drivers of tumor progression. One such target is the E2F1 transcription factor, a key regulator of the cell cycle and a contributor to proliferation, differentiation, apoptosis, metastasis, and chemoresistance in CRC. Previous studies have demonstrated the efficacy of E2F1 silencing via siRNA-loaded nanoliposomes in reducing tumor cell growth, but challenges such as immunogenicity and off-target effects have limited their in vivo application. In this study, we evaluated the potential of gene electrotransfer (GET) as a non-viral delivery system for delivery of therapeutic siRNA targeting E2F1 in the HT-29 CRC model. In vitro experiments showed effective silencing of E2F1 expression and a significant reduction in HT-29 cell survival. Subsequent in vivo studies confirmed the therapeutic potential of siE2F1 GET, with results demonstrating tumor growth delay, decreased proliferation, and increased necrosis in the tumors. This study establishes proof-of-principle for targeting E2F1 in CRC using GET, showcasing its versatility and therapeutic potential.

Language:English
Keywords:colorectal carcinoma, E2F1, gene electrotransfer, GET, silencing, siRNA
Work type:Article
Typology:1.01 - Original Scientific Article
Organization:MF - Faculty of Medicine
BF - Biotechnical Faculty
Publication status:Published
Publication version:Version of Record
Year:2025
Number of pages:10 str.
Numbering:Vol. 165, art. 108994
PID:20.500.12556/RUL-169105 This link opens in a new window
UDC:616-006
ISSN on article:1567-5394
DOI:10.1016/j.bioelechem.2025.108994 This link opens in a new window
COBISS.SI-ID:235435267 This link opens in a new window
Publication date in RUL:12.05.2025
Views:331
Downloads:127
Metadata:XML DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:Bioelectrochemistry
Publisher:Elsevier
ISSN:1567-5394
COBISS.SI-ID:2502484 This link opens in a new window

Licences

License:CC BY-NC-ND 4.0, Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
Link:http://creativecommons.org/licenses/by-nc-nd/4.0/
Description:The most restrictive Creative Commons license. This only allows people to download and share the work for no commercial gain and for no other purposes.

Secondary language

Language:Slovenian
Keywords:kolorektalni rak, E2F1, GET, elektroprenos genov

Projects

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:P3-0003
Name:Razvoj in ovrednotenje novih terapij za zdravljenje malignih tumorjev

Funder:MAECI - Italy, Ministry of Foreign Affairs and International Cooperation
Project number:VN21GR01

Funder:Lega Italiana per la Lotta Contro I Tumori
Name:Evaluation of a novel antifibrotic and antitumor molecule for hepatocellular carcinoma

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back